{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:42:48Z","timestamp":1788259368577,"version":"build-2803163510"},"reference-count":18,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,5,1]]},"DOI":"10.1248\/bpb.b20-00796","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T22:09:29Z","timestamp":1619820569000},"page":"737-741","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetic and Adsorptive Analyses of Administration of Oral Voriconazole Suspension &lt;i&gt;via&lt;\/i&gt; Enteral Feeding Tube in Intensive Care Unit Patients"],"prefix":"10.1248","volume":"44","author":[{"given":"Ryota","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Ohchi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Kitano","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. <i>Clin. Infect. Dis.<\/i>, <b>34<\/b>, 563\u2013571 (2002).","DOI":"10.1086\/324620"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Marks DI, Liu Q, Slavin M. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation. <i>Expert Rev. Anti Infect. Ther.<\/i>, <b>15<\/b>, 493\u2013502 (2017).","DOI":"10.1080\/14787210.2017.1305886"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. <i>J. Clin. Pharmacol.<\/i>, <b>46<\/b>, 235\u2013243 (2006).","DOI":"10.1177\/0091270005283837"},{"key":"4","unstructured":"4) Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, Husain S. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. <i>J. Antimicrob. Chemother.<\/i>, <b>71<\/b>, 1786\u20131799 (2016)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, Mikus G. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. <i>Br. J. Clin. Pharmacol.<\/i>, <b>68<\/b>, 906\u2013915 (2009).","DOI":"10.1111\/j.1365-2125.2009.03534.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). <i>J. Pharm. Sci.<\/i>, <b>99<\/b>, 3291\u20133301 (2010).","DOI":"10.1002\/jps.22109"},{"key":"7","unstructured":"7) Turner RB, Martello JL, Malhotra A. A worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: a systematic review. <i>Int. J. Antimicrob. Agents<\/i>, <b>46<\/b>, 362\u2013366 (2015)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. <i>Nephron<\/i>, <b>16<\/b>, 31\u201341 (1976).","DOI":"10.1159\/000180580"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kurata N, Komatsu C, Heito A, Mori Y. Examination and list of solid preparations being able to administer through feeding tubes. <i>Jpn. J. Pharm. Health Care Sci.<\/i>, <b>27<\/b>, 461\u2013472 (2001).","DOI":"10.5649\/jjphcs.27.461"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Morita TO, Yamaguchi A, Kimura S, Fujii H, Endo K, Izumi K, Saito S, Minami H. Stability of lenalidomide suspension after preparation by a simple suspension method for enteral tube administration. <i>J. Oncol. Pharm. Pract.<\/i>, <b>22<\/b>, 579\u2013583 (2016).","DOI":"10.1177\/1078155215593623"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Suzuki Y, Tokimatsu I, Sato Y, Kawasaki K, Sato Y, Goto T, Hashinaga K, Itoh H, Hiramatsu K, Kadota J. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. <i>Clin. Chim. Acta<\/i>, <b>424<\/b>, 119\u2013122 (2013).","DOI":"10.1016\/j.cca.2013.05.025"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, Hata T. Moment analysis program available on Microsoft Excel<sup>\u00ae<\/sup>. <i>Drug Metab. Pharmacokinet.<\/i>, <b>14<\/b>, 286\u2013293 (1999).","DOI":"10.2133\/dmpk.14.286"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tabata K, Yamaoka K, Yasui H, Fukuyama T, Nakagawa T. Influence of pentobarbitone on <i>in vivo<\/i> local disposition of diclofenac in rat liver. <i>J. Pharm. Pharmacol.<\/i>, <b>48<\/b>, 866\u2013869 (1996).","DOI":"10.1111\/j.2042-7158.1996.tb03989.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tanaka R, Suzuki Y, Goto K, Yasuda N, Koga H, Kai S, Ohchi Y, Sato Y, Kitano T, Itoh H. Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. <i>J. Pharm. Biomed. Anal.<\/i>, <b>165<\/b>, 56\u201364 (2019).","DOI":"10.1016\/j.jpba.2018.11.047"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Suzuki Y, Tanaka R, Oyama N, Nonoshita K, Hashinaga K, Umeki K, Sato Y, Hiramatsu K, Kadota JI, Itoh H. Sensitive and selective quantification of total and free itraconazole and hydroxyitraconazole in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. <i>Clin. Biochem.<\/i>, <b>50<\/b>, 1228\u20131236 (2017).","DOI":"10.1016\/j.clinbiochem.2017.09.011"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Liu Y, Qiu T, Liu Y, Wang J, Hu K, Bao F, Zhang C. Model-based voriconazole dose optimization in chinese adult patients with hematologic malignancies. <i>Clin. Ther.<\/i>, <b>41<\/b>, 1151\u20131163 (2019).","DOI":"10.1016\/j.clinthera.2019.04.027"},{"key":"17","unstructured":"17) Lin XB, Huang F, Tong L, Xia YZ, Wu JJ, Li J, Hu XG, Liang T, Liu XM, Zhong GP, Cai CJ, Chen X. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit. <i>Int. J. Infect. Dis.<\/i>, <b>93<\/b>, 345\u2013352 (2020)."},{"key":"18","unstructured":"18) Veringa A, Ter Avest M, Span LF, van den Heuvel ER, Touw DJ, Zijlstra JG, Kosterink JG, van der Werf TS, Alffenaar JC. Voriconazole metabolism is influenced by severe inflammation: a prospective study. <i>J. Antimicrob. Chemother.<\/i>, <b>72<\/b>, 261\u2013267 (2017)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/5\/44_b20-00796\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T03:30:41Z","timestamp":1619839841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/5\/44_b20-00796\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00796","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}